# US 2017/0281603 A1 · Thiazolide compounds for treating viral infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281603 A1
- Document ID: US20170281603A1
- Status: Published application
- Kind: A1
- Application number: 15/474,267
- Filed: 2017-03-30
- Published: 2017-10-05
- Earliest claimed: 2016-03-31
- Assignees: Romark Laboratories L.C.
- Applicants: Romark Laboratories L.C.
- Inventors: Jean-Francois Rossignol; Maria Gabriella Santoro
- Web page: https://patentgrep.com/patent/US20170281603A1

## CPC

- A61K 31/426: 1,3-Thiazoles
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Thiazolide compounds, such as nitazoxanide and/or tizoxanide, may be used against viruses belonging to the Picornaviridae family or the Paramyxoviridae family.

## Claims

### Claim 1

A method of treating a disease or condition caused by or associated with a virus belonging to the Paramyxoviridae family, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising at least one of nitazoxanide or tizoxanide or a pharmaceutically acceptable salt thereof, wherein the effective amount is an amount which blocks in the subject the maturation of the fusion (F) glycoprotein of the virus.

### Claim 2 (depends on 1)

The method of claim 1, wherein the virus is a virus belonging to the Respirovirus genus.

### Claim 3 (depends on 2)

The method of claim 2, wherein the virus is Sendai virus.

### Claim 4 (depends on 1)

The method of claim 1, wherein the virus is a virus belonging to the Pneumovirus genus.

### Claim 5 (depends on 4)

The method of claim 4, wherein the virus is human respiratory syncytial virus.

### Claim 6 (depends on 4)

The method of claim 4, wherein said administering alleviates at least one symptom of the disease or condition, wherein at least one symptom is selected from rhinitis, coughing, decreased appetite, wheezing, difficulty breathing, fever, bronchiolitis and pneumonia.

### Claim 7 (depends on 1)

The method of claim 1, wherein the virus is a virus belonging to the Henipavirus genus.

### Claim 8 (depends on 7)

The method of claim 7, wherein the virus is Hendra virus.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 10

A method of treating a disease or condition caused by or associated with a virus belonging to the Henipavirus genus, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one of nitazoxanide or tizoxanide or a pharmaceutically acceptable salt thereof,

### Claim 11 (depends on 10)

The method of claim 10, wherein the virus is Hendra virus.

### Claim 12 (depends on 10)

The method of claim 10, wherein the therapeutically effective amount is an amount, which blocks in the subject the maturation of the fusion (F) protein of the virus.

### Claim 13 (depends on 10)

The method of claim 10, wherein the subject is a human.

### Claim 14

A method of treating a disease or condition caused by or associated with a virus belonging to the Picornaviridae family, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one of nitazoxanide or tizoxanide or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 14)

The method of claim 14, wherein the virus belongs to the Enterovirus genus.

### Claim 16 (depends on 15)

The method of claim 15, wherein said administering alleviates at least one symptom of the disease or condition, wherein the at least one symptom is selected from fever, cough, sore throat, nasal obstruction, fatigue, headache, myalgia, and feverishness.

### Claim 17 (depends on 16)

The method of claim 16, wherein said administering a) reduces fever caused by or associated with the disease or condition and b) alleviates at least one symptom of the disease or condition, wherein the at least one symptom is selected from cough, sore throat, nasal obstruction, fatigue, headache, myalgia, and feverishness.

### Claim 18 (depends on 17)

The method of claim 17, wherein the administering a) reduces the fever caused by or associated with the disease or condition, and b) alleviates at least one respiratory symptom caused by or associated with the disease or condition and at least one constitutional symptom associated with the disease or condition, wherein the at least one respiratory symptom is selected from cough, sore throat, and nasal obstruction and wherein the at least constitutional symptom is selected from fatigue, headache, myalgia, and feverishness.

### Claim 19 (depends on 15)

The method of claim 15, wherein the virus is selected from Enterovirus A-J.

### Claim 20 (depends on 15)

The method of claim 15, wherein the virus is selected from Rhinovirus A-C.

### Claim 21 (depends on 14)

The method of claim 14, further comprising administering to the subject a therapeutically effective amount of a direct-acting antiviral agent.

### Claim 22 (depends on 21)

The method of claim 21, wherein the direct-acting antiviral agent is rupintrivir or MK-0608 or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 15)

The method of claim 15, wherein said administering starts within 48 hours of an onset in the subject of at least one symptom of the disease or condition, wherein the at least one symptom is selected from fever, cough, sore throat, nasal obstruction, fatigue, headache, myalgia, and feverishness.

### Claim 24 (depends on 14)

The method of claim 14, wherein the subject is a human.
